Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tremelimumab in Metastatic Urothelial Cancer Post-PD-1/PD-L1
NCT03557918Phase 2Completed
- Start
- Nov 2018
- Primary completion
- Dec 2021
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tremelimumab in urothelial carcinoma (UC). Started Nov 2018; status: completed.
02
Drugs
tremelimumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03557918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03557918.